# A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors

> **NCT07730021** · PHASE1,PHASE2 · RECRUITING · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 392 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** ASP388B
- **DRUG:** Pembrolizumab
- **DRUG:** Carboplatin
- **DRUG:** Oxaliplatin
- **DRUG:** 5-fluorouracil

## Key facts

- **NCT ID:** NCT07730021
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-02
- **Primary completion:** 2030-02-28
- **Final completion:** 2030-05-31
- **Target enrollment:** 392 (ESTIMATED)
- **Last updated:** 2026-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07730021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07730021, "A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07730021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*